Q4 2025 Evaxion A/S Earnings Call Transcript
Key Points
- Evaxion AS (EVAX) reported significant progress in 2025, including a successful collaboration with MSD and the Gates Foundation.
- The company presented positive two-year Phase 2 data for its EVX-01 cancer vaccine, showing a high objective response rate and strong immunogenicity.
- Evaxion AS (EVAX) has a cash runway extending into the second half of 2027, supported by a $32 million cash inflow from various financing activities.
- The AI-Immunology platform received recognition from the Galien Foundation for its advances in human health.
- The company is exploring new applications of its AI-Immunology platform in autoimmune diseases, potentially expanding its market reach.
- MSD chose not to exercise its option over the EVX-B2 candidate for gonorrhea, indicating potential challenges in partnership or data validation.
- The company faces the challenge of translating its technical strengths into meaningful transactions with large-cap pharma companies.
- Evaxion AS (EVAX) is not positioned to take too many products further into the clinic, which may limit its ability to independently advance its pipeline.
- The company is still in the early stages of applying its AI-Immunology platform to autoimmune diseases, with no specific indications yet prioritized.
- Despite progress, the company reported a net loss of $7.7 million for 2025, highlighting ongoing financial challenges.
/-
Thank you for joining us for Evaxion's business update following the reporting of our 2025 full year financial results yesterday. And apologies that this call is 24 hours later than we anticipated for technical reasons.
We are delighted to be here today. My name is Helen Tayton-Martin, and I am honored to be leading this call for the first time as Evaxion's CEO.
We move to the first slide. Okay. So on today's call, we will review the achievements of 2025 and touch on the milestones we anticipate for 2026. Our Chief Scientific Officer, Birgitte Rono, will then walk through our key R&D updates for the year, including the latest innovations from our AI-Immunology platform, after which our CFO, Thomas Schmidt, will walk through our 2025 financial results before we close with a few concluding remarks and take questions.
Right. Moving to the next slide. And of course, our comments and presentation today may contain forward-looking statements and all participants on today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
